PDB Short entry for 2C5X HEADER TRANSFERASE/INHIBITOR 03-NOV-05 2C5X TITLE DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 TITLE 2 PROVIDES INSIGHTS FOR DRUG DESIGN COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CYCLIN DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLIN A2; COMPND 9 CHAIN: B, D; COMPND 10 SYNONYM: CYCLIN A; COMPND 11 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS TRANSFERASE/INHIBITOR, INHIBITION, ACTIVE, INACTIVE, CDK2, CELL KEYWDS 2 CYCLE, CELL DIVISION, KINASE, MITOSIS, SERINE/THREONINE-PROTEIN KEYWDS 3 KINASE, TRANSFERASE, ATP-BINDING, COMPLEX (TRANSFERASE-INHIBITOR), KEYWDS 4 TRANSFERASE-INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE,D.GIBSON,M.MEZNA, AUTHOR 2 M.THOMAS,G.WOOD,S.WANG,M.D.WALKINSHAW,P.M.FISCHER REVDAT 4 13-DEC-23 2C5X 1 REMARK REVDAT 3 03-APR-19 2C5X 1 SOURCE REVDAT 2 24-FEB-09 2C5X 1 VERSN REVDAT 1 01-MAR-06 2C5X 0 JRNL AUTH G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE,D.GIBSON, JRNL AUTH 2 M.MEZNA,M.THOMAS,G.WOOD,S.WANG,M.D.WALKINSHAW,P.M.FISCHER JRNL TITL DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE JRNL TITL 2 CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN. JRNL REF CHEM.BIOL. V. 13 201 2006 JRNL REFN ISSN 1074-5521 JRNL PMID 16492568 JRNL DOI 10.1016/J.CHEMBIOL.2005.11.011 REMARK 2 REMARK 2 RESOLUTION. 2.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 27911 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.203 REMARK 3 R VALUE (WORKING SET) : 0.200 REMARK 3 FREE R VALUE : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1197 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.97 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1975 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.4110 REMARK 3 BIN FREE R VALUE SET COUNT : 91 REMARK 3 BIN FREE R VALUE : 0.3650 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8923 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 56 REMARK 3 SOLVENT ATOMS : 88 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.11 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -3.31000 REMARK 3 B22 (A**2) : -2.45000 REMARK 3 B33 (A**2) : 5.76000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.445 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.338 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 18.517 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.930 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.865 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9230 ; 0.015 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12538 ; 2.918 ; 1.983 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1108 ;12.688 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 396 ;43.654 ;23.965 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1618 ;26.959 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 44 ;25.885 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1412 ; 0.204 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 6898 ; 0.019 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 5860 ; 0.370 ; 0.300 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 6380 ; 0.387 ; 0.500 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 60 ; 0.331 ; 0.300 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 9 ; 0.549 ; 0.500 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5653 ; 3.432 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9066 ; 5.455 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3956 ; 9.316 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3472 ;12.919 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 2 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : A C REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 A 1 A 296 2 REMARK 3 1 C 1 C 296 2 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 TIGHT POSITIONAL 1 A (A): 1180 ; 0.27 ; 0.05 REMARK 3 MEDIUM POSITIONAL 1 A (A): 1188 ; 0.69 ; 0.50 REMARK 3 TIGHT THERMAL 1 A (A**2): 1180 ; 0.70 ; 0.50 REMARK 3 MEDIUM THERMAL 1 A (A**2): 1188 ; 4.15 ; 2.00 REMARK 3 REMARK 3 NCS GROUP NUMBER : 2 REMARK 3 CHAIN NAMES : B D REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 B 175 B 432 2 REMARK 3 1 D 175 D 432 2 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 TIGHT POSITIONAL 2 B (A): 1027 ; 0.20 ; 0.05 REMARK 3 MEDIUM POSITIONAL 2 B (A): 1048 ; 0.58 ; 0.50 REMARK 3 TIGHT THERMAL 2 B (A**2): 1027 ; 0.66 ; 0.50 REMARK 3 MEDIUM THERMAL 2 B (A**2): 1048 ; 3.98 ; 2.00 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2C5X COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 03-NOV-05. REMARK 100 THE DEPOSITION ID IS D_1290026247. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-JUN-03 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.80 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX14.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.44 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 29878 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.900 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 4.000 REMARK 200 R MERGE (I) : 0.16000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 7.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.73000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1OL1 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 22% PEG 3350, 0.1M NA3-CIT, PH 7.80 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.16700 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 77.45550 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 56.17600 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 77.45550 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.16700 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 56.17600 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 GLU B 174 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 GLU D 174 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HIS C 268 O TYR C 269 1.27 REMARK 500 O VAL B 175 N ASP B 177 1.64 REMARK 500 O VAL C 230 N SER C 232 1.90 REMARK 500 O THR B 282 CG2 THR B 285 1.94 REMARK 500 O GLU C 40 NZ LYS D 288 1.96 REMARK 500 O THR A 14 N GLY A 16 2.01 REMARK 500 O HIS D 419 O HOH D 2015 2.04 REMARK 500 NE2 HIS A 71 ND1 HIS B 296 2.04 REMARK 500 O THR C 165 O HOH C 2012 2.04 REMARK 500 OE2 GLU A 224 OG1 THR A 231 2.07 REMARK 500 O ARG C 260 OG SER C 264 2.09 REMARK 500 OD1 ASN B 415 N LYS B 417 2.10 REMARK 500 OD1 ASN D 415 N LYS D 417 2.11 REMARK 500 N ILE C 70 O TYR C 77 2.11 REMARK 500 O THR C 165 O HOH C 2013 2.13 REMARK 500 CB VAL C 164 O HOH C 2013 2.14 REMARK 500 O TYR C 159 N HIS C 161 2.14 REMARK 500 OG1 THR D 383 OG SER D 386 2.14 REMARK 500 O HIS B 419 N VAL B 421 2.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 ND2 ASN B 431 OD1 ASP C 210 2664 1.73 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 THR A 14 N - CA - C ANGL. DEV. = -22.4 DEGREES REMARK 500 VAL A 30 CG1 - CB - CG2 ANGL. DEV. = -9.7 DEGREES REMARK 500 LEU A 32 CB - CG - CD1 ANGL. DEV. = -17.1 DEGREES REMARK 500 PRO A 61 C - N - CA ANGL. DEV. = 11.2 DEGREES REMARK 500 PRO A 102 C - N - CA ANGL. DEV. = 10.8 DEGREES REMARK 500 LEU A 108 CB - CG - CD1 ANGL. DEV. = -15.1 DEGREES REMARK 500 LEU A 124 CB - CA - C ANGL. DEV. = -11.8 DEGREES REMARK 500 LEU A 124 CB - CG - CD1 ANGL. DEV. = -14.3 DEGREES REMARK 500 LEU A 133 CB - CG - CD1 ANGL. DEV. = -10.5 DEGREES REMARK 500 LEU A 255 CB - CG - CD1 ANGL. DEV. = -12.6 DEGREES REMARK 500 ARG A 274 NE - CZ - NH2 ANGL. DEV. = -3.6 DEGREES REMARK 500 LEU A 281 CB - CG - CD2 ANGL. DEV. = -10.6 DEGREES REMARK 500 PRO A 284 C - N - CA ANGL. DEV. = 11.3 DEGREES REMARK 500 LEU B 186 CA - CB - CG ANGL. DEV. = -17.3 DEGREES REMARK 500 LEU B 186 CB - CG - CD1 ANGL. DEV. = 10.4 DEGREES REMARK 500 VAL B 248 CB - CA - C ANGL. DEV. = -11.5 DEGREES REMARK 500 LEU B 302 CB - CG - CD1 ANGL. DEV. = -13.4 DEGREES REMARK 500 LEU B 332 CB - CG - CD1 ANGL. DEV. = -11.9 DEGREES REMARK 500 LEU B 339 CB - CG - CD2 ANGL. DEV. = -12.5 DEGREES REMARK 500 PRO B 346 C - N - CA ANGL. DEV. = 9.6 DEGREES REMARK 500 LEU B 376 CB - CG - CD2 ANGL. DEV. = 11.1 DEGREES REMARK 500 VAL C 18 CB - CA - C ANGL. DEV. = -12.5 DEGREES REMARK 500 LEU C 25 CA - CB - CG ANGL. DEV. = -15.4 DEGREES REMARK 500 LEU C 25 CB - CG - CD2 ANGL. DEV. = -13.7 DEGREES REMARK 500 VAL C 64 CB - CA - C ANGL. DEV. = -13.7 DEGREES REMARK 500 PRO C 102 C - N - CA ANGL. DEV. = 10.9 DEGREES REMARK 500 LEU C 124 CB - CA - C ANGL. DEV. = -12.5 DEGREES REMARK 500 LEU C 124 CA - CB - CG ANGL. DEV. = 14.7 DEGREES REMARK 500 LEU C 124 CB - CG - CD1 ANGL. DEV. = -11.1 DEGREES REMARK 500 LEU C 133 CB - CG - CD2 ANGL. DEV. = -11.4 DEGREES REMARK 500 CYS C 177 CA - CB - SG ANGL. DEV. = -11.6 DEGREES REMARK 500 LEU C 189 CB - CG - CD1 ANGL. DEV. = -10.6 DEGREES REMARK 500 PRO C 204 C - N - CA ANGL. DEV. = 9.7 DEGREES REMARK 500 ASP C 206 CB - CG - OD2 ANGL. DEV. = -5.5 DEGREES REMARK 500 ASP C 270 N - CA - CB ANGL. DEV. = 11.3 DEGREES REMARK 500 ASP C 270 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES REMARK 500 ARG C 274 NE - CZ - NH2 ANGL. DEV. = -3.2 DEGREES REMARK 500 PRO D 176 C - N - CA ANGL. DEV. = -23.1 DEGREES REMARK 500 PRO D 176 C - N - CD ANGL. DEV. = 19.4 DEGREES REMARK 500 ASP D 181 CB - CG - OD1 ANGL. DEV. = 5.8 DEGREES REMARK 500 LEU D 227 CB - CG - CD1 ANGL. DEV. = -14.2 DEGREES REMARK 500 LEU D 232 CB - CG - CD1 ANGL. DEV. = -15.3 DEGREES REMARK 500 MET D 246 CG - SD - CE ANGL. DEV. = 10.9 DEGREES REMARK 500 ARG D 250 NE - CZ - NH1 ANGL. DEV. = -5.0 DEGREES REMARK 500 LEU D 320 CA - CB - CG ANGL. DEV. = -16.4 DEGREES REMARK 500 PRO D 346 C - N - CA ANGL. DEV. = 13.5 DEGREES REMARK 500 LEU D 362 CB - CG - CD2 ANGL. DEV. = -11.2 DEGREES REMARK 500 ASP D 393 CB - CG - OD2 ANGL. DEV. = 5.7 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 14 143.68 171.74 REMARK 500 TYR A 15 55.97 0.63 REMARK 500 ARG A 36 89.71 -34.65 REMARK 500 THR A 39 30.72 -82.93 REMARK 500 GLU A 40 -37.25 -133.97 REMARK 500 HIS A 60 150.78 164.14 REMARK 500 ASP A 68 142.29 176.16 REMARK 500 THR A 72 -159.31 -78.49 REMARK 500 LYS A 88 -72.54 -48.73 REMARK 500 ALA A 93 2.40 -69.12 REMARK 500 LEU A 96 -63.08 88.37 REMARK 500 PRO A 100 117.35 -35.89 REMARK 500 LEU A 101 -59.55 -17.16 REMARK 500 ARG A 122 37.46 74.85 REMARK 500 ARG A 126 -15.18 63.25 REMARK 500 LYS A 129 146.67 -174.29 REMARK 500 ASP A 145 81.13 64.88 REMARK 500 PHE A 146 31.90 -99.82 REMARK 500 HIS A 161 59.02 -110.78 REMARK 500 GLU A 162 103.37 -34.04 REMARK 500 THR A 165 156.35 122.49 REMARK 500 LEU A 166 -115.33 -96.74 REMARK 500 TRP A 167 -47.85 57.50 REMARK 500 THR A 182 -52.55 -28.72 REMARK 500 MET A 196 -48.08 -23.79 REMARK 500 ALA A 201 116.81 -14.85 REMARK 500 PHE A 203 56.04 -140.64 REMARK 500 THR A 218 -71.27 -107.72 REMARK 500 ASP A 223 -158.12 -123.54 REMARK 500 TRP A 227 84.78 -152.36 REMARK 500 VAL A 230 -69.17 -19.71 REMARK 500 THR A 231 -19.57 -46.98 REMARK 500 ARG A 245 129.35 -39.33 REMARK 500 LYS A 278 -70.27 -23.90 REMARK 500 PRO A 284 -37.66 -35.29 REMARK 500 THR A 290 -115.83 -128.92 REMARK 500 LYS A 291 46.76 175.22 REMARK 500 PRO B 176 27.37 -18.75 REMARK 500 CYS B 193 30.81 -82.10 REMARK 500 LYS B 226 64.29 37.24 REMARK 500 ARG B 250 -27.32 -39.49 REMARK 500 ASP B 284 74.35 17.93 REMARK 500 THR B 303 67.31 27.50 REMARK 500 PHE B 304 17.71 35.77 REMARK 500 THR B 316 -50.58 -29.53 REMARK 500 HIS B 321 51.96 -102.64 REMARK 500 ASN B 326 116.40 173.71 REMARK 500 LEU B 336 -74.75 -52.30 REMARK 500 GLU B 338 -53.44 -29.53 REMARK 500 LEU B 339 -32.26 -33.70 REMARK 500 REMARK 500 THIS ENTRY HAS 134 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 GLY A 11 GLU A 12 145.07 REMARK 500 GLY A 13 THR A 14 -145.08 REMARK 500 TYR A 19 LYS A 20 145.17 REMARK 500 ASN A 59 HIS A 60 -149.92 REMARK 500 ASN A 62 ILE A 63 147.41 REMARK 500 MET A 91 ASP A 92 140.81 REMARK 500 LEU A 166 TRP A 167 121.28 REMARK 500 HIS A 295 LEU A 296 -146.17 REMARK 500 ILE B 270 TYR B 271 137.19 REMARK 500 PRO B 272 PRO B 273 149.06 REMARK 500 LEU B 336 GLY B 337 125.80 REMARK 500 SER B 340 LEU B 341 149.61 REMARK 500 ALA B 344 ASP B 345 133.74 REMARK 500 ASP B 345 PRO B 346 145.85 REMARK 500 LEU B 423 LEU B 424 127.75 REMARK 500 PRO B 427 GLU B 428 -146.68 REMARK 500 THR B 429 LEU B 430 -148.94 REMARK 500 GLU C 8 LYS C 9 147.35 REMARK 500 GLY C 11 GLU C 12 147.84 REMARK 500 TYR C 15 GLY C 16 -135.75 REMARK 500 ILE C 70 HIS C 71 -139.79 REMARK 500 HIS C 161 GLU C 162 141.31 REMARK 500 VAL C 164 THR C 165 147.89 REMARK 500 THR C 165 LEU C 166 -141.34 REMARK 500 ASP C 206 SER C 207 -141.84 REMARK 500 GLY D 198 TYR D 199 -135.16 REMARK 500 ASP D 283 ASP D 284 -145.45 REMARK 500 PRO D 324 ALA D 325 149.71 REMARK 500 ALA D 344 ASP D 345 -148.18 REMARK 500 ASP D 345 PRO D 346 141.23 REMARK 500 PRO D 346 TYR D 347 -141.74 REMARK 500 GLY D 369 GLN D 370 137.32 REMARK 500 LEU D 423 LEU D 424 142.62 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 VAL C 64 -10.41 REMARK 500 MET C 233 -19.97 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MTW A1297 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MTW C1297 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKU RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P- REMARK 900 F-PHE)-NH2 REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE DESIGN DBREF 2C5X A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2C5X C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2C5X B 174 432 UNP P20248 CCNA2_HUMAN 174 432 DBREF 2C5X D 174 432 UNP P20248 CCNA2_HUMAN 174 432 SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 B 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 B 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 B 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 B 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 B 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 B 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 B 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 B 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 B 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 B 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 B 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 B 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 B 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 B 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 B 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 B 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 B 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 B 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 B 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 C 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 D 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 D 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 D 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 D 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 D 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 D 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 D 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 D 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 D 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 D 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 D 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 D 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 D 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 D 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 D 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 D 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 D 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 D 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 D 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU HET MTW A1297 28 HET MTW C1297 28 HETNAM MTW HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1- HETNAM 2 MTW YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL) HETNAM 3 MTW AMMONIUM FORMUL 5 MTW 2(C19 H15 N7 O2) FORMUL 7 HOH *88(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 ALA A 93 1 7 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 ALA A 170 LEU A 175 1 6 HELIX 6 6 THR A 182 ARG A 199 1 18 HELIX 7 7 SER A 207 GLY A 220 1 14 HELIX 8 8 GLY A 229 MET A 233 5 5 HELIX 9 9 ASP A 247 VAL A 252 1 6 HELIX 10 10 ASP A 256 LEU A 267 1 12 HELIX 11 11 SER A 276 ALA A 282 1 7 HELIX 12 12 HIS A 283 GLN A 287 5 5 HELIX 13 13 TYR B 178 CYS B 193 1 16 HELIX 14 14 THR B 207 LYS B 226 1 20 HELIX 15 15 GLN B 228 SER B 244 1 17 HELIX 16 16 LEU B 249 GLU B 269 1 21 HELIX 17 17 GLU B 274 ILE B 281 1 8 HELIX 18 18 THR B 287 LEU B 302 1 16 HELIX 19 19 THR B 310 LEU B 320 1 11 HELIX 20 20 ASN B 326 ILE B 342 1 17 HELIX 21 21 ASP B 343 LEU B 348 1 6 HELIX 22 22 LEU B 351 GLY B 369 1 19 HELIX 23 23 PRO B 373 GLY B 381 1 9 HELIX 24 24 LEU B 387 ALA B 401 1 15 HELIX 25 25 PRO B 402 HIS B 404 5 3 HELIX 26 26 GLN B 407 LYS B 414 1 8 HELIX 27 27 ASN B 415 HIS B 419 5 5 HELIX 28 28 PRO C 45 LYS C 56 1 12 HELIX 29 29 LEU C 87 ALA C 93 1 7 HELIX 30 30 PRO C 100 HIS C 121 1 22 HELIX 31 31 LYS C 129 GLN C 131 5 3 HELIX 32 32 ALA C 170 LEU C 175 1 6 HELIX 33 33 SER C 181 ARG C 199 1 19 HELIX 34 34 SER C 207 GLY C 220 1 14 HELIX 35 35 GLY C 229 MET C 233 5 5 HELIX 36 36 ASP C 247 VAL C 251 5 5 HELIX 37 37 ASP C 256 LEU C 267 1 12 HELIX 38 38 SER C 276 ALA C 282 1 7 HELIX 39 39 HIS C 283 VAL C 289 5 7 HELIX 40 40 TYR D 178 CYS D 193 1 16 HELIX 41 41 GLY D 198 GLN D 203 5 6 HELIX 42 42 THR D 207 TYR D 225 1 19 HELIX 43 43 GLN D 228 LEU D 243 1 16 HELIX 44 44 LEU D 249 GLU D 269 1 21 HELIX 45 45 GLU D 274 ILE D 281 1 8 HELIX 46 46 THR D 287 LEU D 302 1 16 HELIX 47 47 THR D 310 LEU D 320 1 11 HELIX 48 48 ASN D 326 SER D 340 1 15 HELIX 49 49 ASP D 343 LEU D 348 1 6 HELIX 50 50 LEU D 351 THR D 368 1 18 HELIX 51 51 PRO D 373 GLY D 381 1 9 HELIX 52 52 THR D 383 ALA D 401 1 19 HELIX 53 53 PRO D 402 HIS D 404 5 3 HELIX 54 54 GLN D 407 TYR D 413 1 7 HELIX 55 55 ASN D 415 HIS D 419 5 5 SHEET 1 AA 5 PHE A 4 GLU A 12 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 PHE A 80 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 LYS C 9 0 SHEET 2 CA 5 VAL C 18 ASN C 23 -1 O LYS C 20 N VAL C 7 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 CISPEP 1 GLN B 323 PRO B 324 0 -12.78 CISPEP 2 GLN D 323 PRO D 324 0 -9.82 SITE 1 AC1 14 ILE A 10 GLY A 13 VAL A 18 ALA A 31 SITE 2 AC1 14 LYS A 33 PHE A 80 GLU A 81 PHE A 82 SITE 3 AC1 14 LEU A 83 HIS A 84 GLN A 131 ASN A 132 SITE 4 AC1 14 LEU A 134 ASP A 145 SITE 1 AC2 12 ILE C 10 ALA C 31 LYS C 33 PHE C 80 SITE 2 AC2 12 GLU C 81 LEU C 83 HIS C 84 GLN C 85 SITE 3 AC2 12 ASP C 86 GLN C 131 LEU C 134 ASP C 145 CRYST1 74.334 112.352 154.911 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013453 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008901 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006455 0.00000